Autoprzeciwciała rozpoznające białka mieliny jako biomarkery w stwardnieniu rozsianym

• Autorzy: Jaśkiewicz E.

Warianty tytułu

EN

Antimyelin atuoantibodies as biological markers in multiple sclerosis

• Języki publikacji: PL

Abstrakty

PL

Stwardnienie rozsiane (SM) jest chroniczną chorobą ośrodkowego układu nerwowego, charakteryzującą się występowaniem rozsianych ognisk demielinizacji włókien nerwowych. Heterogenność objawów i przebiegu klinicznego choroby wiąże się z koniecznością indywidualnej klasyfikacji pacjentów w oparciu o czynniki genetyczne, kliniczne oraz immunologiczne. Do czynników, które brane są pod uwagę należą autoprzeciwciała, bezpośrednio związane z humoralną odpowiedzią autoimmunologiczną występującą w SM. W przedstawionej pracy podsumowano stan wiedzy na temat autoprzeciwciał rozpoznających trzy główne antygeny mieliny: MBP, PLP oraz MOG. Uważa się, że mogą być one użytecznymi biomarkerami w klasyfikacji i przewidywaniu przebiegu SM, co w przyszłości przyczyni się do wyboru zindywidualizowanej, efektywnej terapii SM.

EN

Multiple sclerosis (MS) is a human inflamatory demyelinating disease of the central nervous system. Because of heterogeneity in phenotypic expression of the disease there is a need for subtyping of patients by genetical, clinical and neuroimmunological parameters. Evidence for a possible role of autoantibodies to myelin antigens as biological markers for MS comes from several studies indicating the importance of humoral response in MS. This reviev summarizes the findings on autoantibodies recognizing three major myelin antigens: MBP, PLP and MOG. It is belived that these antibodies serving as biomarkers will help to establish individual, pathogenic subtype and disease status, that will allow to treat patients selectively and more efficiently.

Słowa kluczowe

PL

stwardnienie rozsiane; autoprzeciwciała; biomarkery

EN

multiple sclerosis; autoatibodies; biomarkers

• Wydawca: Wydawnictwo Uniwersytetu Humanistyczno-Przyrodniczego im. Jana Długosza w Częstochowie
• Czasopismo: Chemistry, Environment, Biotechnology
• Rocznik: 2010
• Tom: Vol. 14
• Strony: 153--164
• Opis fizyczny: Bibliogr. 47 poz.

Twórcy

autor

Jaśkiewicz E.

• Instytut Immunologii i Terapii Doświadczalnej PAN im. Ludwika Hirszfelda, Wrocław,

Bibliografia

• 1. Hafler D.A., Slavik J.M., Anderson D.E., O’Connor K.C., De Jager P., Baecher-Allan C., Multiple sclerosis, Immunol.Rev. 2005, 204, 208–231.
• 2. Nosewothy J.H., Lucchinetti C., Rodrigues M., Weinshenker B.G., Multiple sclerosis, New Engl. J. Med. 2000, 343, 938–952.
• 3. Selmaj K., Stwardnienie rozsiane-kryteria diagnostyczne i naturalny przebieg choroby, Polski Przegląd Neurologiczny, 2005, 1, 99–105.
• 4. Stasiołek M., Myćko M., Selmaj K., Patogeneza stwardnienia rozsianego, Polski Przegląd Neurologiczny, 2005, 1, 92–98.
• 5. Gilden D.H., Infectious causes of multiple sclerosis., http://neurology.thelancet.com 2005, 4, 195–202.
• 6. Achiron a., Gurevich M., Friedman N., i wsp., Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity, Ann. Neurol. 2004, 55, 410–417.
• 7. Tutaj M., Szczepanik M., Mechanizmy regulacji odpowiedzi immunologicznej w modelu stwardnienia rozsianego u myszy, Postępy Hig. Med. Dosw. 2006, 60, 571–583.
• 8. Correale J., Bassani M., Oligoclonal bands and antibody responses in multiple sclerosis, J. Neurol. 2002, 249, 375–389.
• 9. Dharmasaroja P., Specificity of autoantibodies to epitopes of myelin proteins in multiple sclerosis, J. Neurol. Sci. 2003, 206, 7–13.
• 10. Smidt S., Candidate autoantigens in multiple sclerosis, Multiple scler. 1995, 5, 147–160.
• 11. Jaśkiewicz E., Epitopy na białkach mieliny rozpoznawane przez autoprzeciwciała obecne u chorych na stwardnienie rozsiane, Postępy. Hig. Med. Dosw. 2004, 58, 472–482.
• 12. Somers K., Govarts C., Stinissen., Somers V., Multiplexing approaches for autoantibody profiling in multiple sclerosis, Autoimmunity Rev. 2009, 8, 573–579.
• 13. Lalive P.H., Menge T., Delarasse C., Gaspera D., Pham-Dinh D., Villoslada P., Von Budingen H.C., Genain C.P., Antibodies to native myelin ologodendrocyte glycoprotein are serologic markers if early inflamation in multiple sclerosis, Proc. Natl. Acad. Sci. USA. 2006, 103, 2280–2285.
• 14. Jaśkiewicz E., Jedynak A., Zioło E., Recombinant forms of myelin basic protein and proteolipid protein expressed in CHO cells, Acta Biochimica Polonica, 2005, 52, 863–866.
• 15. Jaśkiewicz E., Michałowska–Wender G., Pyszczek A., Wender M., Recombinant forms of myelin antigens expressed on CHO cells as a tool for identification of autoantibodies in sereum of MS patients, Folia Neuropatologica 2010, 48, 45–48.
• 16. Brunner C., Lassman H., Waehneldt T.V., Mattieu J.M., Linnington C., Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats, J. Neurochem. 1989, 52, 296–304.
• 17. Roth H.J., Kronquist K.E., Kerlero de Rosbo N., Crandall B.F., Campagnoni A.T., Evidence for the, expression of four myelin basic protein variants in the developing human spinal cord through cDNA cloning, J. Neurosci Res. 1987, 17, 321–328.
• 18. Wood D.D, Moscarello M.A., The isolation, characterization, and lipid-aggregating properties of a citrulline containing myelin basic protein, J Biol Chem. 1989, 264, 5121–5127.
• 19. Ridsdale R., Beniac D.R., Tompkins T., Moscarello M.A., Harauz G., Threedimensional structure of Myelin basic protein. Reconstruction via angular reconstruction of randomly oriented single particles, J. Biol. Chem. 1997, 272, 4261–4268.
• 20. Ridsdale R., Beniac D.R., Tompkins T., Moscarello M.A., Harauz G., Threedimensional structure of Myelin basic protein. Molecular modeling and considerations of predicted structures in multiple sclerosis, J. Biol. Chem. 1997, 272, 4269–4275.
• 21. Waren K.G., Catz I., Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue., J. Neurol. Sci 1993, 115, 169–176.
• 22. O’Conor K.C., Chitnis T., Griffin D.E., Piyasirisilp S., Bar-Or A., Khoury S., Wucherpfennig K.W., Hafler D.A., Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions, J. Neuroimmunol. 2003, 136, 140–148.
• 23. Warren K.G., Catz I., Steinmam L., Fine specificity of antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and model of its features, Proc. Nat. Acad. Sci. USA 1995, 92, 11061– 11065.
• 24. Bates I.R., Boggs J.M., Feix J.B., Harauz G., An immunodominant epitope of myelin basic protein is an amphipathic alpha-helix, J Biol Chem. 2004
• 25. Wucherpfennig K.W., Strominger J.L., Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein, Cell 1995, 80, 695–705.
• 26. Warren K.G., Catz I., An extensive search for autoantibodies to myelin basic protein in cerebrospinal fluid of non-multiple-sclerosis patients: Implication for the pathogenesis of multiple sclerosis, Eur. Neurol. 1999, 42, 95–104.
• 27. Stoffel W., Hollen H., Giersiefen H., Structure and molecular arrangement of proteolipid protein of central nervous system myelin, Proc. Natl. Acad. Sci. USA 1984, 81, 5012–5016.
• 28. Boison D., Stoffel W., Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice, Proc. Natl. Acad .Sci U S A. 1994, 91, 11709–11713.
• 29. Trotter J.L., Pelfrey C.M., Trotter A.L., Selvidge J.A., Gushleff K.C., Mohanakumar T., McFarland H.F., T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects, J. Neuroimmunol. 1998, 84, 172–178.
• 30. Sun J.B., Olsson T., Wang W.Z., Xiao B.G., Kostulas V., Fredrikson S., Ekre H.P., Link H., Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls, Eur. J. Immunol. 1991, 21, 1461–1468.
• 31. Warren K.G., Catz I., Johnson E., Mielke B., Anti-myelin basic protein and antiproteolipid protein specific forms of multiple sclerosis, Ann. Neurol. 1994 , 35, 280–289.
• 32. Amiguet P., Gardinier M.V., Zanetta J.P., Matthieu J.M., Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein, J. Neurochem. 1992, 58, 1676–1682.
• 33. Hjelmstrom P., Penzotti J.E., Henne R.M., Lybrand T.P., A molecular model of myelin oligodendrocyte glycoprotein, J Neurochem. 1998, 71, 1742174–9.
• 34. Clements C.S., Reid H.H., Beddoe T., Tynan F.E., Perugini M.A., Johns T.G., Bernard C.C., Rossjohn J., The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis, Proc. Natl. Acad. Sci USA, 2003, 100, 11059–11064.
• 35. Bischof F., Bins A., Durr M., Zevering Y., Melms A., Kruisbeek A.M., A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response, J. Immunol. 2004, 173, 600–606.
• 36. Genain C.P., Nguyen M.P., Letvin N.L., Pearl R., Davin R.L., Adelman M., Lees M.B., Linington C., Hauser S.L., Antibody facilitation of multiple sclerosis-like lesions in nonhuman primate, J. Clin. Invest. 1995, 96, 2966–2974.
• 37. Genain C. P., Cannella B., Hauser S. L., Raine C.S., Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat. Med. 1999, 5, 170–175.
• 38. Haase C.G., Guggenmos J., Brehm U., Andersson M., Olsson T., Reindl M., Schneidewind J.M., Zettl U.K., Heidenreich F., Berger T., Wekerle H., Hohfeld R., Linington C., The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls, J. Neuroimmunol. 2001, 114, 220–225.
• 39. von Budingen H.C., Hauser S.L., Ouallet J.C., Tanuma N., Menge T., Genain C.P., Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination, Eur. J. Immunol. 2004, 34, 2072–2083.
• 40. Mathey E., Breithaupt C., Schubart A.S., Linington C., Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire, Eur. J. Immunol. 2004, 34, 2065–2071.
• 41. Reindl M., Khalil M., Berger T., Antibodies as biological markers for pathophysiological processes in MS, J. Neurol. 2006, 180, 50–62.
• 42. Bielekova B., Martin R., Development of biomarkers in multiple scelosis, Brain, 2004, 127, 1463–1478.
• 43. Berger T., Reindl M., Multiple sclerosis: disease biomarkers as indicated by pathophysiology, J. Neurol. Sci 2007, 259, 21–26.
• 44. Berger T., Rubner P., Schautzer F., Egg r., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M., Antimyelin antiboodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event, N. Engl. J. Med. 2003, 349, 139–145.
• 45. Lim E.T., Berger T., Reindl M., Dalton C.M., Fernando K., Keir G., i wsp., Antimyelin antibodies do not allow earlier diagnosis of multiple sclerosis, Mult. Scler. 2005, 11, 492–494.
• 46. Gaerthner S., De Graaf K.L., Greve B., Weissert R., Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis, Neurology, 2004, 63, 2381–2383.
• 47. Lolli F., Mulinaci B., Carotenuto A., Boneti B., Sabatino G., i wsp., An Nglucosylated peptide detecting disease specific autoantibodies, biomarkers of multiple sclerosis, Proc. Natl. Acad. Sci. USA 2005, 102, 10273–10278.